[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.8.87. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 11, 1994

Combination Products as First-Line Pharmacotherapy

Author Affiliations

Division of Cardio-Renal Drug Products (HFD-110) Center for Drug Evaluation and Research Food and Drug Administration 5600 Fishers Lane, Rockville, MD 20857

Arch Intern Med. 1994;154(13):1429-1430. doi:10.1001/archinte.1994.00420130015002

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

IN THE COURSE of evaluation for approval, a single-component drug is occasionally found to be unambiguously less effective or more dangerous than others. Such a drug may, nevertheless, be a valuable addition to the armamentarium, but it will be approved only as a second-line therapy, to be used only after others have been found to be ineffective or contraindicated. For example, bepridil is approved for the treatment of chronic stable angina, but its associated adverse drug reactions (ADRs) are sufficiently more severe than those of other approved antianginal products that bepridil is not approved as first-line therapy.

Drugs like bepridil are unusual. Most single-component products are approved as first-line therapy. Betaxolol, bisoprolol, chlorthalidone, and hydrochlorothiazide are separately approved as first-line therapy for hypertension, so some physicians may find it unremarkable that fixed-dose combinations of betaxolol and chlorthalidone and of bisoprolol and hydrochlorothiazide are also approved as first-line therapy. In fact,

First Page Preview View Large
First page PDF preview
First page PDF preview
×